EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

End-of-Induction Response and Tolerability of High-Risk Neuroblastoma Treated with Chemoimmunotherapy—Modified N7 Regimen with Dinutuximab Beta

Evelyn R Lu iD, Calvin P L Hoo, Ho Ming Cheung, I W C Wong iD, K F Kevin Fung, Sylvia L Y Chang, Anselm C W Lee, Eric C H Fu, Dennis T L Ku iD, Jeffrey P W Yau iD, Matthew M K Shing iD, Christy Y K Mak iD und 2 weitere

Cancers · 23.03.2026 · 18 (6) · 1028

DOI: 10.3390/cancers18061028 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 23.03.2026. Verfasst von Evelyn R Lu und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Paediatrics and Adolescent Medicine, Hong Kong Children's Hospital, Hong Kong, China. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The integration of anti-disialoganglioside GD2 (anti-GD2) immunotherapy during induction chemotherapy has emerged as a promising strategy to improve outcomes in high-risk neuroblastoma (HR-NB). This study evaluated the end-of-induction (EOI) response and tolerability of a modified N7 induction regimen combined with dinutuximab beta in a Hong Kong paediatric cohort.

Methods

A retrospective territory-wide analysis was conducted on nine HR-NB patients treated from 2022 to 2025. They received a modified N7 chemotherapy backbone with dinutuximab beta (17.5 mg/m2/day for 4 days per cycle), alongside granulocyte–macrophage colony-stimulating factor (GM-CSF) and low-dose interleukin-2. Response was assessed using the Revised International Neuroblastoma Response Criteria (INRC), and toxicity was graded according to the Common Terminology Criteria for adverse events (CTCAE).

Results

The EOI objective response rate was 78% (7/9 patients) for the primary tumour site and 100% at metastatic sites. No patient exhibited progressive disease. A modified Curie score of ≤2 on MIBG scan was achieved in 78% of patients. Grade 3 or higher toxicities, including neutropenic fever, enterocolitis, and capillary leak syndrome, were observed in eight patients but were manageable.

Conclusions

The incorporation of dinutuximab beta into a modified N7 induction regimen demonstrates a satisfactory EOI response rate and a manageable safety profile in children with HR-NB. These preliminary results support the feasibility of this chemoimmunotherapy approach and warrant further investigation in larger cohorts to confirm its efficacy in long-term survival outcomes.

Schlagwörter

Stichwörter der Autor:innen

anti-GD2dinutuximab betahigh-risk neuroblastomaimmunotherapyinduction chemotherapymodified N7

Autor:innen und Institutionen

  • Department of Paediatrics and Adolescent Medicine, Hong Kong Children's Hospital, Hong Kong, China.
  • Department of Paediatrics and Adolescent Medicine, School of Clinical Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
  • Nuclear Medicine Unit, Department of Diagnostic and Interventional Radiology, Queen Elizabeth Hospital, Hong Kong, China.
  • Department of Radiology, Hong Kong Children's Hospital, Hong Kong, China.
  • Neuro-Oncology Section, Hospital for Sick Children, Toronto, ON M5G 1X8, Canada.

ORCID-Profile: Evelyn R Lu, I W C Wong, Dennis T L Ku, Jeffrey P W Yau, Matthew M K Shing, Christy Y K Mak

Zitieren

APA

Lu, E. R., Hoo, C. P. L., Cheung, H. M., Wong, I. W. C., Fung, K. F. K., Chang, S. L. Y., Lee, A. C. W., Fu, E. C. H., Ku, D. T. L., Yau, J. P. W., Shing, M. M. K., Mak, C. Y. K., Liu, A. P. Y., & Chan, G. C. F. (2026). End-of-Induction Response and Tolerability of High-Risk Neuroblastoma Treated with Chemoimmunotherapy—Modified N7 Regimen with Dinutuximab Beta. Cancers, 18(6), 1028. https://doi.org/10.3390/cancers18061028

Vancouver

Lu ER, Hoo CPL, Cheung HM, Wong IWC, Fung KFK, Chang SLY, et al. End-of-Induction Response and Tolerability of High-Risk Neuroblastoma Treated with Chemoimmunotherapy—Modified N7 Regimen with Dinutuximab Beta. Cancers. 2026;18(6):1028. doi:10.3390/cancers18061028

BibTeX
@article{Lu2026,
  author = {Lu, Evelyn R and Hoo, Calvin P L and Cheung, Ho Ming and Wong, I W C and Fung, K F Kevin and Chang, Sylvia L Y and Lee, Anselm C W and Fu, Eric C H and Ku, Dennis T L and Yau, Jeffrey P W and Shing, Matthew M K and Mak, Christy Y K and Liu, Anthony P Y and Chan, Godfrey C F},
  title = {End-of-Induction Response and Tolerability of High-Risk Neuroblastoma Treated with Chemoimmunotherapy—Modified N7 Regimen with Dinutuximab Beta},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {6},
  pages = {1028},
  doi = {10.3390/cancers18061028}
}
Kostenlos starten →